ストックスクリーナーアプリを入手
0.0126
2.44%
0.0003
前日終値:
$0.0123
開ける：
$0.0126
24時間の取引高:
216
Relative Volume:
1.02
時価総額：
$N/A
収益：
-
当期純損益:
$-48.85M
株価収益率:
-0.00545
EPS:
-2.31
ネットキャッシュフロー:
$-46.25M
1週間 パフォーマンス:
+2.44%
1か月 パフォーマンス:
+2.44%
6か月 パフォーマンス:
-61.23%
1年 パフォーマンス:
-99.66%
1日の値動き範囲:
$0.0126
$0.0126
1週間の範囲:
$0.0126
$0.0126
52週間の値動き範囲:
$0.0101
$0.041
Vincerx Pharma Inc Stock (VINC) Company Profile
Compare VINC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VINC
Vincerx Pharma Inc
|
0.0126 | 0 | 0 | -48.85M | -46.25M | -2.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.17 | 117.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.03 | 82.63B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
742.79 | 45.82B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.38 | 42.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
305.39 | 33.54B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-01-14 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-01 | 開始されました | SVB Leerink | Outperform |
| 2021-09-13 | 開始されました | Laidlaw | Buy |
| 2021-08-25 | 開始されました | B. Riley Securities | Buy |
Vincerx Pharma Inc (VINC) 最新ニュース
VINC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Head to Head Comparison: Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO) - Defense World
Critical Review: Vincerx Pharma (NASDAQ:VINC) & Trevena (NASDAQ:TRVN) - Defense World
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Analyzing Vincerx Pharma (NASDAQ:VINC) & Petros Pharmaceuticals (NASDAQ:PTPI) - Defense World
Head to Head Analysis: Vectura Group (OTCMKTS:VEGPF) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. (VINC) Stock forecasts - Yahoo
Analyzing Neoleukin Therapeutics (NASDAQ:NLTX) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. (VINC) stock price, news, quote and history - Yahoo
Vincerx Pharma, Inc.Common Stock (NQ: VINC - FinancialContent
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders - ACCESS Newswire
Vincerx Pharma, Inc. Announces Additional Adjournment of - GlobeNewswire
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - The Manila Times
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR - GlobeNewswire
Vincerx Pharma, Inc. Announces Adjournment of Special MeetingWill Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal - Yahoo Finance
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
Global Digital Holdings Inc. cancelled the acquisition of Vincerx Pharma, Inc. in a reverse merger transaction. - marketscreener.com
VINC: Vincerx Pharma to dissolve, with minimal or no distributions expected for stockholders - TradingView
VINC Stock Price, News & Analysis - Stock Titan
VINC Stock Price and Chart — OTC:VINC - TradingView
VINC stock touches 52-week low at $0.17 amid sharp annual decline - Investing.com
Vincerx Pharma Announces Suspension and Intent to Delist Common Stock from Nasdaq - Nasdaq
vincerx pharma cancels merger, initiates wind-down activities - Investing.com
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down - Fierce Biotech
Vincerx Pharma ends merger talks, begins asset wind-down - Investing.com
VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline - Investing.com
Vincerx Pharma Inc. (VINC) reports earnings - qz.com
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis - Fierce Biotech
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart - Fierce Biotech
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - Yahoo Finance
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - Yahoo Finance
Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma, Inc. Announces Reverse Stock Split - GlobeNewswire
Vincerx Pharma enters at-the-market equity offering deal - Investing.com
Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc.VINC | FinancialContent - FinancialContent
Vincerx acquisition leads to C-suite shake-up—Chutes & Ladders - Fierce Biotech
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Asianet Newsable
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Stocktwits
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - qz.com
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Vincerx reports two complete responses in VIP943 study By Investing.com - Investing.com UK
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - Investing News Network
Vincerx Pharma Inc (VINC) 財務データ
収益
当期純利益
現金流量
EPS
0.28%
17.88%
大文字化:
|
ボリューム (24 時間):